May 22, 2020 / 8:40 PM / 4 days ago

BRIEF-U.S. FDA Approves Takeda's Alunbrig As A First-Line Treatment For Patients With Rare Form Of Lung Cancer

May 22 (Reuters) - Takeda Pharmaceutical Co Ltd:

* U.S. FDA APPROVES TAKEDA’S ALUNBRIG® (BRIGATINIB) AS A FIRST-LINE TREATMENT OPTION FOR PATIENTS DIAGNOSED WITH RARE AND SERIOUS FORM OF LUNG CANCER

* TAKEDA PHARMACEUTICAL - FDA APPROVAL EXPANDS ALUNBRIG’S CURRENT INDICATION TO INCLUDE FIRST-LINE SETTING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below